95%Confidence
0Views
FDASource
2026-05-26Date
Summary
Acella Pharmaceuticals' naproxen suspension is contaminated with lead and lithium, posing serious health risks and likely triggering a recall. This could result in significant financial liabilities and damage to Acella's brand, affecting its distribution partnerships.
Actionable: Short Acella Pharmaceuticals or avoid its products, and monitor for class-action lawsuits.
AI Confidence: 95%
Data Points
firmAcella Pharmaceuticals, LLC
classificationClass II
statusOngoing
distributionNationwide
productNAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now